Why the study?
To demonstrate the application of next-generation sequencing in developing a time-saving and cost-effective diagnostic method to detect SNVs and CNVs in a single test for muscular dystrophies.
Does amplicon panel-based next-generation sequencing provide an effective diagnostic method for detecting variants in muscular dystrophy patients?
Does amplicon panel-based next-generation sequencing provide an effective diagnostic method for detecting variants in muscular dystrophy patients?
Panel-based next-generation sequencing provides a high-throughput, affordable, and time-saving diagnostic strategy for muscular dystrophy, potentially superior to MLPA.
NGS panel testing may unify SNV/CNV detection in suspected MD; leaves open prospective validation before routine adoption.
Muscular Dystrophies (MDs) are a group of inherited diseases and heterogeneous in nature. To date, 40 different genes have been reported for the occurrence and/or progression of MDs. This study was conducted to demonstrate the application of next-generation sequencing (NGS) in developing a time-saving and cost-effective diagnostic method to detect single nucleotide variants (SNVs) and copy number variants (CNVs) in a single test. A total of 123 cases clinically suspected of MD were enrolled in this study. Amplicon panel-based diagnosis was carried out for 102 (DMD/BMD) cases and the results were further screened using multiplex ligation-dependent probe amplification (MLPA). Whilst in the case of LGMD (N = 19) and UMD (N = 2), only NGS panel-based analysis was carried out. We identified the large deletions in 74.50% (76/102) of the cases screened with query DMD or BMD. Further, the large deletion in CAPN3 gene (N = 3) and known SNV mutations (N = 4) were identified in LGMD patients. Together, the total diagnosis rate for this amplicon panel was 70.73% (87/123) which demonstrated the utility of panel-based diagnosis for high throughput, affordable, and time-saving diagnostic strategy. Collectively, present study demonstrates that the panel based NGS sequencing could be superior over to MLPA.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: